BSO LLC, Golden, CO
Is BSO LLC an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names BSO LLC in Golden, CO, first registered Jan 24, 2024 and most recently registered Oct 17, 2026. FDA lists its last inspection as Jun 27, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 2/11/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Golden, CO
- Initial registration
- Jan 24, 2024
- Most recent registration
- Oct 17, 2026
- Last inspection
- Jun 27, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- N/A
- Action on last inspection
- Response Letter Issued 2/11/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as BSO LLC (dba Belmar Select Outsourcing), Golden, CO, a 503B facility, with 1 listed action, including 1 Form 483 (2025).
| Document | |||
|---|---|---|---|
| Jun 27, 2025 | Form 483 | 483 Issued 06/27/2025 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists BSO, LLC, Golden, CO (FEI number 3030548360), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jun 27, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3030548360 | 1274469 |
Form 483s FDA has published for this site
- Jun 27, 2025: Form 483 to BSO, LLC, published Aug 12, 2025. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jun 16, 2025 to Jun 27, 2025: 8 observations
- Firm on the cover
- BSO, LLC, 741 Coporate Cir Ste A-H, Golden, CO 80401-5602
- FEI number
- 3030548360
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P.O. Box 25087) Denver, co 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
Specifically,
Your firm failed to establish and document adequate validation of the <Redacted B4> sterilization process used for Estradiol Pellets (6 mg, 10 mg, 12.5 mg, 15 mg, 18 mg, 20 mg, 25 mg, 37.5 mg, 50mg).
a. You implemented a new container-closure system for Estradiol Pellets, but your sterilization validation (BSO.ST.002.1 R) did not include a method suitability study or calculation of a recovery factor (RF) to assess the efficiency of microbial recovery from the new configuration. Additionally, your firm has changed to a new bioburden test method ID <Redacted B4> since the original validation, which can significantly affect recovery efficiency. You provided method suitability data from <Redacted B4> and lD <Redacted B4> Estradiol pellets packaged <Redacted B4> vials produced from your Lakewood, CO facility. You also provided method suitability data for <Redacted B4> vials. ...
Observation 2
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
SOP 12, Visual inspection ofPellets (BSO Lakewood & Golden), Version 26.0, Effective Date 03/19/2025, does not have defined criteria for operator re-qualification outside of <Redacted B4> retraining, particularly in cases where re-qualification may be warranted due to performance issues, process deviations, or procedural changes. As a result, operators may remain in a qualified status despite demonstrating issues performing critical operations, without any reassessment of their competency. For example:
i. On 04/02/2025, during the 100% visual inspection of Estradiol 12.5 mg pellets Lot # <Redacted B4> Operator found a total of thirty-five (35) defects, including nineteen (19) "Black Speck" (Scrap code: BS), and twelve (12) "Contaminant in vial" (Scrap Code: CVL). ...
Observation 3
The written stability program for drug products does not include specific test methods.
Specifically,
a. Lack of Photostability Studies for Light Sensitive Product: Your firm manufactures Estradiol pellets, which are light-sensitive product, yet the product is packaged and released in clear, non-light-resistant containers. Stability Study BSO.SS.001 , Estradiol Pellet Stability Study-Day Report, signed 03/24/2025, does not contain any data to demonstrate that the packaging protects the drug from photodegradation. No photostability studies have been performed on the drug product in its container-closure system to demonstrate its protection from light, and no justification has been provided for the omission.
the drug from photodegradation. No photostability studies have been performed on the drug
product in its container-closure system to demonstrate its protection from light, and no justification has been provided for the omission.
b. ...
Observation 4
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.
Specifically,
Your firm manufactures Estradiol Pellets (6 mg, 10 mg, 12.5 mg, 15 mg, 18 mg, 20 mg, 25 mg, 37.5 mg, 50mg) intended for subcutaneous implantation, designed to release drug over a prolonged period. However, you do not perform dissolution testing as part of batch release. This omission of dissolution testing could potentially lead to the distribution of subpotent drug products, as well as potential dose dumping, inconsistent release rates, and incomplete drug release.
Observation 5
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
Specifically,
The <Redacted B4> (BSO-016), used in the production of Estradiol granulate at the firm, has not been qualified with respect to its ability to remove residual solvents. Estradiol granulate contains <Redacted B4> is a granulating solvent. The equipment qualification study (BSO.EQ.016 <Redacted B4>) for this <Redacted B4> was performed using <Redacted B4> and <Redacted B4> and did not evaluate performance using <Redacted B4>.
No study was provided to demonstrate equivalency between the qualification materials and the actual product formulation. No data were provided to demonstrate that the <Redacted B4> is capable of consistently and safely removing <Redacted B4> under the parameters used during routine production. ...
Observation 6
The master production and control records are deficient in that they do not include complete manufacturing and control instructions, specifications, special notations and precautions to be followed.
Specifically,
a. Inade quate Documentation and Control: The Estradiol Granulate Production-Batch Production Record (Form 45-09E) does not record the <Redacted B4> & parameters set point applied during the <Redacted B4> step and that it was maintained throughout the entire run of <Redacted B4> Section 8.6.8 of SOP 45 <Redacted B4> A <Redacted B4> Granulation (BSD-Lakewood & Golden), Version 22, Effective Date 03/27/2025, states "Ensure that <Redacted B4> has reached an operating temperature of <Redacted B4>, C, then placing in a <Redacted B4> in the <Redacted B4>. A., There is no mention of verification of the <Redacted B4> setting before use. During qualification of the <Redacted B4> & <Redacted B4> (BSO.EQ.016. lR), the had an operating setting of <Redacted B4> and a set point <Redacted B4>. On 06/18/2025, during the granulation Estradiol 15 mg Pellets, Lot # <Redacted B4>, I observed an alarm on the <Redacted B4> & <Redacted B4> noting the <Redacted B4> rise to <Redacted B4>. ...
Observation 7
Written production and process control procedures are not followed in the execution of production and process control functions.
Specifically,
Section 7.1.3.1 of SOP 58, In-Process, Weight, and Hardness Samplingfor Pellets (BSO-Lakewood & Golden), Version 25, Effective Date 02/07/2025, states "Regardless of weighing method, documentation will occur on, pellets pressed <Redacted B4>". The following deviations from this procedure were observed on 06/19/2025, during the production of Estradiol 15 mg Pellets, Lot <Redacted B4>.
a. Incorrect Sampling Freguency: Technicians conducted in-process checks every 25 pellets instead of evening <Redacted B4> pellets as specified in the SOP and Estradiol Pellet Manufacture Batch Production Record-Form 46-12E.
b lncomplete Documentation: Midway through the production of the batch, Technicians stopped documenting the results of in-process checks, once all available spaces in the Batch Production Record where occupied.
documenting the results of in-process checks, once all available spaces in the Batch Production Record where occupied.
Observation 8
Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically,
On 6/17/2025, I observed the <Redacted B4> cleaning process for ISO 8 Inspection Room, where Estradiol pellets are weighed, vialed, and capped, and noted the following deviations:
a. Improper Floor Cleaning Technigue: During floor cleaning with sporicidal agent, Technician did not follow the method outlined in Section 8.2.2 of <Redacted B4> 163.01, Cleanroom Cleaning Techniques (BSO-Golden), Version 2.0, Effective Date 01/06/2025, which require <Redacted B4> from <Redacted B4> & <Redacted B4> aL <Redacted B4>, and <Redacted B4> Section 8.2.9.2 of SOP 163, Cleaning/Sanitation of Facility/Cleanroom (BSO-Golden), Version 6.0, Effective Date 05/21/2025, states "Enter and clean at location <Redacted B4> to avoid waling on clean surf aces." Instead, the technician stepped on wet floor surfaces immediately after._<Redacted B4>. and placed chairs and tables directly on top of treated areas without allowing for the required contact (dwell) time.
b. ...
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (BSO LLC). That is not a finding beyond this index’s search.
The BSO LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA’s 503B list also names BSO LLC, Lakewood, CO. Each is a separate listing with its own records; a similar name does not show they are the same firm.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.